The Oxford Vaccine Group’s Com-COV vaccine trials (Com-COV, Com-COV2, Com-COV3) are studying the use of different combinations of approved COVID-19 vaccines.
These studies are being led by the Oxford Vaccine Group (Com-COV and Com-COV2 Chief Investigator Professor Maheshi Ramasamy; Com-COV3 Chief Investigator Dr Angela Minassian), and delivered by a network of trial sites across the UK. The Com-COV studies are funded by the Vaccine Task Force, National Institute for Health Research (NIHR) and the Coalition for Epidemic Preparedness Innovations (CEPI).
Our researchers are working hard to get the results available to inform UK immunisation policy as quickly as possible. We ask that the media do not continue to contact researchers while this critical work is underway, and to use the media contact form for press enquiries.